Brought to you by 
Rakuten Aspyrian raises $150mm via Series C round
23 Aug 2018
Executive Summary
Rakuten Aspyrian Inc. (formerly known as Aspyrian Therapeutics) raised $150mm through its Series C round led by company chairman and CEO of Rakuten Inc., Hiroshi Mikitani. The company is developing photoimmunotherapies for cancer and will use the Series C funds to advance lead compound ASP1929 into Phase III trials by the end of 2018 for recurrent head and neck squamous cell carcinomas. Funds will also go towards manufacturing scale-up for future commercialization of the candidate, build-up of commercial operations to support launching ASP1929 in the US, Europe, and Japan, and potential expansion of research for the candidate in other cancers.
Deal Industry
- Pharmaceuticals
-
Biotechnology
-
Large Molecule
- Antibodies
-
Large Molecule
Deal Status
- Final
Deal Type
-
Financing
- Venture Financing
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Rakuten Aspyrian raises $150mm via Series C round
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice